Menu
1 min read · estimated
APPROVED USE
What FDA approved
Continued treatment for adults with acute myeloid leukemia in first complete remission, with or without incomplete count recovery, after intensive induction chemotherapy who could not complete intensive curative therapy.
LAMPGEN ANALYSIS
Why it matters
Established oral maintenance in this remission setting with a formulation distinct from injectable azacitidine.
What research teams should watch
Do not substitute injectable azacitidine; reconcile the cycle schedule and plan serial blood counts.
PRIMARY RECORDS